MSCL — Satellos Bioscience Balance Sheet
0.000.00%
Last trade - 00:00- CA$53.01m
- CA$13.43m
- 30
- 32
- 98
- 53
Annual balance sheet for Satellos Bioscience, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.99 | 0.065 | 4.87 | 1.92 | 39.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.414 | 0.449 | 0.528 | 0.26 | 0.583 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1.46 | 0.543 | 5.44 | 2.23 | 40.3 |
| Net Property, Plant And Equipment | 0.006 | 0.003 | 0.008 | 0.008 | 0.019 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 1.47 | 0.546 | 12.6 | 6.2 | 44.3 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.808 | 1.3 | 2.1 | 2.83 | 3.62 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.808 | 1.3 | 2.1 | 2.83 | 3.62 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.661 | -0.75 | 10.5 | 3.37 | 40.7 |
| Total Liabilities & Shareholders' Equity | 1.47 | 0.546 | 12.6 | 6.2 | 44.3 |
| Total Common Shares Outstanding |